The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026, for gedatolisib in HR+/HER2-/PIK3CA wild-type (“WT”) advanced breast cancer (“ABC”) Results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 study of gedatolisib regimens in HR+/HER2- ABC published in Journal of Clinical Oncology Topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study are expected to be released in the second quarter of 2026 Management to host webcast and conference call today, March 25, 2026, at 4:30 p.m. EDTMINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial...

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year...

Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle Initial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical conference in 2026 Cash balance of $295.1 million on December 31, 2025, including cash, cash equivalents and investments, is expected to fund operations into 2029SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025.  “2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with deep autoimmune experience, right-sized our workforce to be a responsible...

Aix-en-Provence, 25 March 2026 (6:00 p.m.) HIGHCO: GOOD FINANCIAL PERFORMANCE IN 2025 (ADJUSTED HEADLINE PBIT UP 6.5% TO €8.04 M AND ADJUSTED EPS UP BY 20.8% TO €0.33); STRATEGIC REFOCUSING ON PROMOTION ACTIVATION Business growth in 20252025 gross profit of €66.65 m on a reported basis (up 9.2% including Sogec and Budgetbox) and €62.1 m LFL1 (up 1.8%). Organic growth in the Activation division driven by the good business momentum in France with the development of the HighCo Nifty and HighCo Merely solutions (up 6.7% LFL), the decline in Mobile businesses (down 7.3% LFL) and the decline, as expected, in the Consulting and In-store Media Selling division (down 4.9% LFL). Growth in businesses in France (up 3.9% LFL) and decline in International business (down 11.8% LFL).Increase in adjusted results in 2025Adjusted headline PBIT2 of...

Quadient FY 2025 results: Revenue of €1,036m, current EBIT margin at 13.0% Ambition raised for Digital, set to become Quadient’s largest and most profitable Solution by 2030 Key highlightsConsolidated revenue of €1,036 million, down 3.2% organically, in line with updated FY2025 guidance Strong growth in Digital, with ARR at €250 million, up 10% organically yoy, and further EBITDA margin expansion to 18.0% Mail EBITDA margin sustained at a high level of 27.1%, despite stronger decline in revenue due to low point in the US renewal cycle for mail equipment Double-digit organic growth in Lockers revenue of 11.4%, with strong improvement in profitability Group current EBIT of €135 million, down 2.2% organically, in line with updated FY2025 guidance Net attributable loss of €68 million, impacted by €124 million impairment of Mail goodwill Proposed...

BEIJING, March 25, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results for 2025 as of December 13, 2025. 2025 marked InnoCare’s 10th anniversary and a milestone year of transformative growth and strategic execution. The Company achieved its first full year profitability, secured two new drug application (NDA) approvals, enhanced market penetration of its core products, accelerated globalization, and made breakthroughs across multiple pipelines. With numerous “China First” achievements, InnoCare continues to accelerate its 2.0 development strategy, demonstrating its strong ability to translate scientific innovations into sustainable long-term growth. Financial HighlightsRevenue grew 135.3% year-on-year...

Estimates Reflect $34.3M in Total Assets and $13.6M in Net Assets Following Share Consolidation Singapore, March 25, 2026 (GLOBE NEWSWIRE) — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group” or the “Company”), a global leader in on-demand workforce solutions and integrated facilities management (IFM), today announced that, based on 2025 unaudited financials and the share count as of March 23, 2026, its total assets of approximately $34.3 million equated to approximately $8.03 per share of common stock, and its net assets of approximately $13.6 million equated to approximately $3.18 per share. These estimates reflect preliminary financial data derived from management’s period-end closing process for the 2025 fiscal year, adjusted for the 4,278,935 shares of common stock outstanding post-consolidation. During the period, YY Group...

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028 SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for...

Revenue Growth and Continued Adoption of SynCardia Total Artificial Heart TUCSON, Ariz., March 25, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the year ended December 31, 2025. The year reflected a transformational period for the Company highlighted by revenue growth, improved operating performance, and a strengthened balance sheet following the successful completion of the Company public listing and related capital raises. Key Financial HighlightsRevenue of $4.9 million, an increase of 12.5 percent compared to 2024 Product revenue of $4.7 million representing 96 percent of total revenue Gross margin was (4.1 percent)...

– New Products and Grand Design Expansion Drive Strong Motorhome RV Performance – – Top- and Bottom-Line Growth Reflect Diversified Portfolio and Operational Discipline – – $100 Million Debt Redemption Further Strengthens Balance Sheet – – Company Maintains Fiscal 2026 Guidance for Revenue and Adjusted EPS – EDEN PRAIRIE, Minn., March 25, 2026 (GLOBE NEWSWIRE) — Winnebago Industries, Inc. (NYSE: WGO), a leading manufacturer of outdoor recreation products, today reported financial results for the Fiscal 2026 second quarter ended February 28, 2026. Second Quarter Fiscal 2026 Financial SummaryNet revenues of $657.4 million compared to $620.2 million in the second quarter of Fiscal 2025 Gross profit of $85.6 million, representing 13.0% gross margin, compared to $83.1 million in the second quarter of Fiscal 2025 Net income of $4.8...